RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+22.9%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.54B
AUM Growth
+$381M
Cap. Flow
+$151M
Cap. Flow %
9.83%
Top 10 Hldgs %
42.85%
Holding
66
New
16
Increased
21
Reduced
18
Closed
6
Avg Time Held
1 year
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1 year

Top Buys

Rank Stock Value
1
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$31.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.7M
3
RGNX icon
Regenxbio
RGNX
+$24.5M
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$23.6M
5
ICUI icon
ICU Medical
ICUI
+$23.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$51.5M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$47.7M
3
ARRY icon
Array Biopharma Inc
ARRY
+$41M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$39.4M
5
CNC icon
Centene
CNC
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.68%
2 Financials 0.93%
3 Miscellaneous 0.83%
4 Communication Services 0.56%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SGRY icon
51
Surgery Partners
SGRY
$1.94B
$5.92M 0.38%
+303,500
New +$5.9M
2017 Q1
0 quarters
AVXS
52
DELISTED
AveXis, Inc. Common Stock
AVXS
$3.45M 0.22%
+45,349
New +$2.81M
2017 Q1
0 quarters
ACRS icon
53
Aclaris Therapeutics
ACRS
$498M
$2.71M 0.18%
90,700
-3,500
-4% -$101K
2016 Q4
1 quarter
RARX
54
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.36M 0.15%
110,769
-69,541
-39% -$1.33M
2016 Q4
1 quarter
AUPH icon
55
Aurinia Pharmaceuticals
AUPH
$2.21B
$1.03M 0.07%
140,243
+103,500
+282% +$478K
2015 Q4
5 quarters
UNH icon
56
UnitedHealth
UNH
$355B
$298K 0.02%
1,820
– –
2016 Q3
2 quarters
AMED icon
57
DELISTED
Amedisys
AMED
$247K 0.02%
+4,826
New +$230K
2017 Q1
0 quarters
ADVM icon
58
DELISTED
Adverum Biotechnologies
ADVM
$60K ﹤0.01%
2,224
– –
2016 Q2
3 quarters
CSLT
59
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$37K ﹤0.01%
10,229
– –
2016 Q2
3 quarters
CNC icon
60
Centene
CNC
$34.7B
– –
-1,033,196
Closed -$29.2M –
IBB icon
61
iShares Biotechnology ETF
IBB
$10.4B
– –
-13,500
Closed -$1.19M –
IRTC icon
62
iRhythm Holdings
IRTC
$3.5B
– –
-228,800
Closed -$6.86M –
NVRO icon
63
DELISTED
NEVRO CORP.
NVRO
– –
-260,380
Closed -$18.9M –
ARIA
64
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-3,838,376
Closed -$47.7M –
WOOF icon
65
DELISTED
VCA Inc.
WOOF
– –
-70,040
Closed -$4.81M –
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2017 Portfolio in Review

As of Q1 2017, Redmile Group held 66 positions worth $1.54B, up 33% from $1.16B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $151M of net new capital in Q1 2017, opening 16 new positions and adding to 21 existing holdings. Its largest new stake was Syneos Health, Inc. Class A Common Stock: 633,779 shares worth $29.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $51.5M trimmed.

  • Redmile Group's largest Q1 2017 buy was Syneos Health, Inc. Class A Common Stock: 633,779 shares worth $29.1M.
  • Redmile Group added most to Alder Biopharmaceuticals in Q1 2017, an estimated $21.9M increase.
  • Redmile Group's biggest Q1 2017 reduction was Seagen Inc. Common Stock, cutting an estimated $51.5M.
  • Redmile Group fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $47.7M.
  • Redmile Group's ten largest holdings make up 43% of its $1.54B portfolio in Q1 2017.
  • Redmile Group opened 16 new positions and closed 6 in Q1 2017.
  • Redmile Group's portfolio value rose 33% quarter-over-quarter to $1.54B.

Based on Redmile Group's 13F filing for Q1 2017, filed 15 May 2017.